Curcumin for Renal Transplant Health

Recruiting in Palo Alto (17 mi)

Overseen byPierpaolo Di Cocco, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Illinois at Chicago

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

The primary goal of this study is to investigate if curcumin is beneficial for kidney transplant recipients, a population with extensive baseline vascular dysfunction and cognitive impairment who have few treatment options. The possible mechanisms by which curcumin improves vascular function will be evaluated as well as whether curcumin improves cognitive function in these patients.

Research Team

Pierpaolo Di Cocco, MD, PhD

Principal Investigator

University of Illinois at Chicago

Eligibility Criteria

This trial is for adults over 18 who have received a kidney transplant from either a living or deceased donor. It's not open to those who've had multiple organ transplants or were taking curcumin before their kidney transplant.

Inclusion Criteria

I have received a kidney transplant from a living or deceased donor.

I am older than 18 years.

Exclusion Criteria

I was taking curcumin before my transplant.

I have had a transplant involving multiple organs.

Treatment Details

Interventions

Curcumin (Polyphenol)

Trial OverviewThe study is testing if curcumin can help improve blood vessel function and brain health in people who have had a kidney transplant, comparing it with a placebo (a substance with no therapeutic effect).

Participant Groups

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Curcumin Arm (Arm 1)Experimental Treatment1 Intervention

20 subjects will be randomized (1:1) to this arm and receive curcumin for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood samples and questionnaires.

Group II: Placebo Arm (Arm 2)Placebo Group1 Intervention

20 subjects will be randomized (1:1) to this arm and receive placebo for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood samples and questionnaires.

Curcumin is already approved in India, China for the following indications: